The ascendancy of Viagra and its influence on the drug landscape presents a complicated question for traders. While the initial sales figures were remarkable, the intellectual property has lapsed, leading to a flood of off-brand alternatives that are chipping away at earnings. Furthermore, the market is facing challenges related to population trend